Biosimilars

Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria

Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobi...

Shots: The EC has granted marketing authorization for Epysqli, a biosimilar refere...

Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab

Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab

Shots: The EMA has accepted the MAA for the proposed biosimilar denosumab (Prolia...

Celltrion’s Yuflyma (biosimilar, adalimumab) Receives the US FDA’s Approval for Multiple Indications

Celltrion’s Yuflyma (biosimilar, adalimumab) Receives the US FDA’s Approval for Multiple Indications

Shots: The US FDA has approved Yuflyma (adalimumab-aaty) as the ninth biosimilar r...

Amneal Reports the Commercial Availability of Fylnetra (biosimilar, pegfilgrastim) in the US

Amneal Reports the Commercial Availability of Fylnetra (biosimilar, pegfilgrastim) in the US

Shots: The company launch Fylnetra, a biosimilar referencing Neulasta in the US ma...

Sandoz Entered into an Agreement with Just - Evotec Biologics to Develop and Manufacture Multiple Biosimilar

Sandoz Entered into an Agreement with Just - Evotec Biologics to Develop and Manufacture Multiple Biosimilar

Shots: The companies collaborated to develop and manufacture multiple biosimilar p...

Alvotech Reports an Initiation of AVT05, a Proposed Biosimilar for Simponi and Simponi Aria to Treat Moderate to Severe Rheumatoid Arthritis

Alvotech Reports an Initiation of AVT05, a Proposed Biosimilar for Simponi and Simponi Aria to Treat Moderate to Severe Rheumatoid...

Shots: The company initiates the P-II confirmatory patient study of AVT05, a biosi...

Image